Literature DB >> 7897396

AF64A-induced brain damage and its relation to dementia.

H Hörtnagl1.   

Abstract

Several data obtained in the AF64A-model are of particular relevance for our understanding of the pathogenesis and progression of Alzheimer's disease. The AF64A-induced withdrawal of cholinergic function in the rat hippocampus was associated with reversible functional changes in other neurotransmitters, including noradrenaline, serotonin, somatostatin and glutamate, thereby mimicking changes in Alzheimer's disease. Identical changes in markers for synaptic vesicles were found in Alzheimer's disease and AF64A-model. A study on the role of gender revealed a higher susceptibility to the neurotoxic action of AF64A in female rats. The cholinergic deficit was also responsible for a disinhibition of the negative feedback regulation of glucocorticoids. Increased exposure to glucocorticoids, however, enhanced the vulnerability of hippocampal cholinergic neurons to AF64A. These data indicate that the AF64A-induced cholinergic deficit in the rat brain represents a reliable tool to study several mechanisms possibly involved in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7897396     DOI: 10.1007/978-3-7091-9350-1_19

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  3 in total

Review 1.  The hippocampus and cognitive impairments.

Authors:  E B Arushanyan; E V Beier
Journal:  Neurosci Behav Physiol       Date:  2008-10

2.  MKC-231, a choline-uptake enhancer: (1) long-lasting cognitive improvement after repeated administration in AF64A-treated rats.

Authors:  Tomoko Bessho; Ken Takashina; Junichi Eguchi; Teiko Komatsu; Ken-Ichi Saito
Journal:  J Neural Transm (Vienna)       Date:  2008-05-07       Impact factor: 3.575

3.  MKC-231, a choline uptake enhancer: (2) Effect on synthesis and release of acetylcholine in AF64A-treated rats.

Authors:  Ken Takashina; Tomoko Bessho; Reiko Mori; Junichi Eguchi; Ken-Ichi Saito
Journal:  J Neural Transm (Vienna)       Date:  2008-04-30       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.